source
- Sarepta appoints former AbbVie R&D chief Michael Severino as new CEO amid DMD regulatory outlookSarepta Therapeutics announced that Michael Severino, who previously led Tessera Therapeutics and served as AbbVie’s head of research and development, will become the company’s chief executive. Sev…
- FDA doubts efficacy of Capricor’s Duchenne stem-cell therapy after Phase 3 missThe U.S. Food and Drug Administration said Monday that Capricor Therapeutics’ stem‑cell treatment for Duchenne muscular dystrophy failed to meet the primary goals of its Phase 3 trial, contradictin…